Document Detail


Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.
MedLine Citation:
PMID:  23350937     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Little is known as to the potential for over-treatment of young men diagnosed with prostate cancer. We show that for men aged ≤55 years with PSA screen-detected disease, 45% of the tumours are classified as very low risk and 85% of these have favourable pathology, yet most are actively treated. These findings raise the spectre of over-treatment for a group of men likely to be affected by treatment side-effects. OBJECTIVE: To identify a population of young men (aged <55 years at diagnosis) with very-low-risk prostate cancer (stage cT1c, with prostate-specific antigen [PSA] density of <0.15 ng/mL/g, Gleason score ≤6, and ≤2 positive biopsy cores with <50% tumour involvement) that may be candidates for active surveillance (AS). PATIENTS AND METHODS: We queried a Department of Defense tumour registry and hard-copy records for servicemen diagnosed with prostate cancer from 1987 to 2010. Statistical analyses were undertaken using Fisher's exact and chi-square testing. RESULTS: From 1987-1991 and 2007-2010, PSA screen-detected tumours diagnosed in men aged ≤55 years rose >30-fold. Data for a subset of men (174) with PSA screen-detected cancer were evaluable for disease risk assessment. Of the 174 men with screen-detected disease, 81 (47%) had very-low-risk disease. Of that group, 96% (78/81) selected treatment and, of 57 men undergoing radical prostatectomy (RP), the tumours of 49 (86%) carried favourable pathology (organ confined, <10% gland involvement, Gleason ≤6). CONCLUSIONS: Nearly half of young men with PSA screen-detected prostate cancer are AS candidates but the overwhelming majority seek treatment. Considering that many tumours show favourable pathology at RP, there is a possibility that these patients may benefit from AS management.
Authors:
Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd
Related Documents :
24278607 - Human health risk assessment of trichloroethylene from industrial complex a.
23398137 - Racial/ethnic differences in cancer prevention beliefs: applying the health belief mode...
23955257 - Prognostic implications of egfr and her-2 alteration assessed by immunohistochemistry a...
23646887 - Promoting resilience among parents and caregivers of children with cancer.
23202287 - Comparative effectiveness of minimally invasive versus open lymphadenectomy in urologic...
19531227 - Low nkp30, nkp46 and nkg2d expression and reduced cytotoxic activity on nk cells in cer...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-25
Journal Detail:
Title:  BJU international     Volume:  -     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 BJU International.
Affiliation:
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Why do five-membered heterocyclic compounds sometimes not participate in polar Diels-Alder reactions...
Next Document:  More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantat...